For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240222:nRSV9865Da&default-theme=true
RNS Number : 9865D AstraZeneca PLC 22 February 2024
22 February 2024 11:00 GMT
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that, on 20 February 2024, an award of
the Company's ordinary shares of $0.25 each (Ordinary Shares) under the
AstraZeneca Investment Plan (AZIP) vested to Pascal Soriot, Executive Director
and Chief Executive Officer.
The AZIP award was granted on 24 March 2016 and was subject to a four-year
performance period followed by a four-year holding period before vesting.
Application of the performance measures specified at the time of grant
resulted in 50% of the AZIP award entering the holding period.
Following the reinvestment of dividends accrued during the performance and
holding periods and the withholding of shares to satisfy certain tax
obligations arising on vesting, Mr Soriot acquired Ordinary Shares as detailed
in the table below:
PDMR Ordinary Shares acquired under the AZIP
Pascal Soriot 12,345
For tax purposes, the fair market value of an Ordinary Share at vest was
10,418 pence, being the closing price on the last trading day preceding the
vesting.
Further details are set out in the attached notification, made in accordance
with the requirements of the EU Market Abuse Regulation (since it forms part
of UK law pursuant to the European Union (Withdrawal) Act 2018).
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Pascal Soriot
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name AstraZeneca PLC
b) LEI PY6ZZQWO2IZFZC3IOL08
4i Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of US$0.25 each in AstraZeneca PLC
Identification code
GB0009895292
b) Nature of the transaction Acquisition of Ordinary Shares pursuant to a vesting under the AstraZeneca
Investment Plan, for nil consideration.
c) Price(s) and volume(s)
Price(s) Volume(s)
0 12,345
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
e) Date of the transaction 20 February 2024
f) Place of the transaction Outside a trading venue
d)
Aggregated information
- Aggregated volume
- Price
Not applicable - single transaction
e)
Date of the transaction
20 February 2024
f)
Place of the transaction
Outside a trading venue
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on social media @AstraZeneca (http://www.twitter.com/AstraZeneca) .
Contacts
For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUASVRSKUUUAR